Modern gene therapies aim to prevent the inheritance of mutant mitochondrial DNA (mtDNA) from mother to offspring by using a third-party mtDNA background. Technological limitations mean that these therapies may result in a small amount of maternal mtDNA admixed with a majority of third-party mtDNA. This situation is unstable if the mother's mtDNA experiences a proliferative advantage over the third-party mtDNA, in which case the efficacy of the therapy may be undermined. Animal models suggest that the likelihood of such a proliferative advantage increases with increasing genetic distance between mother and third-party mtDNA, but in real therapeutic contexts the genetic distance, and so the importance of this effect, remains unclear. Here we harness a large volume of available human mtDNA data to model random sampling of mother and third-party mtDNAs from real human populations. We show that even within the same haplogroup, genetic differences around 20-80 SNPs are common between mtDNAs. These values are sufficient to lead to substantial segregation in murine models, over an organismal lifetime, even given low starting heteroplasmy, inducing increases from 5% to 35% over one year. Randomly pairing mothers and third-party women in clinical contexts thus runs the risk that substantial mtDNA segregation will compromise the beneficial effects of the therapy. We suggest that choices of 'mtDNA donors' be based on recent shared maternal ancestry, or, preferentially, explicit haplotype matching, in order to reduce the potential for problems in the implementation of these therapies.
Introduction
Mitochondria are small organelles within eukaryotic cells that are vital for the normal aerobic production of ATP, the 'universal' biochemical energy carrier. Each mitochondrion, of which there are many in any given cell, carries at least one copy of its own, small genome (mitochondrial or mtDNA), distinct from the large genome stored in the nucleus. While there are good reasons for retaining some genes in the mitochondrion (Johnston and Williams, 2016) , a challenging biochemical environment and comparative lack of efficient DNA repair mechanisms allows a higher mutation rate there than in the nucleus (Alexeyev et al. , 2013) .
Differences in the sequence of mitochondrial DNA can arise at the level of individuals (population diversity) or different mitochondria in the same cell (heteroplasmysee below). In humans, mtDNA is inherited uniparentally, via the mother's egg cell; recombination is usually negligible between human mtDNAs (Hagelberg, 2003 , Hagstrom et al. , 2014 . Given the non-recombining nature of the mitochondrial genome, such polymorphisms as exist can be expressed in terms of a straightforward phylogenetic tree (see Fig. 1A ). The sum of polymorphisms in an mtDNA sequence is known as a haplotype, and any hierarchical clade of haplotypes is a haplogroup. Since inheritance is uniparental, mtDNA haplogroups are strongly susceptible to genetic drift, and this has given rise to pronounced haplogroup pattern differences between geographical areas, especially on a continental scale (see Fig.  1B ).
Figure 1. A) Relationship between human mtDNA haplogroups.
Haplogroup labels and tree structure for human mtDNA groups; MRCA is most recent common ancestor. B) Typical haplogroups in pre-colonial human populations by approximate geography. We have omitted higher-order haplogroups of which many sub-groups are presented (e.g. N & R). Based on data from MitoMAP (Lott et al., 2013) and references therein.
While most mitochondrial diversity in humans is neutral or near-neutral (Chinnery and Hudson, 2013) , certain mtDNA mutations in humans can cause fatal, incurable diseases (for example, mt3243A>G, causing the inherited disease MELAS), often manifesting when the proportion of mutated mtDNA molecules in a cellular population exceeds a threshold Turnbull, 2005, Wallace and Chalkia, 2013) . Clinical approaches to prevent the inheritance of diseases resulting from damaging mutations in mtDNA are a focus of current medical research. Cutting-edge therapies including pronuclear transfer and chromosomal spindle transfer attempt to address the inheritance of mutant mtDNA from a maternal carrier by transferring the nuclear genome (either as the pair of pronuclei or the chromosomal spindle) into an enucleated third-party oocyte or enucleated zygote with non-pathogenic mtDNA (Brown et al. , 2006 , Craven et al. , 2010 , Tachibana et al. , 2009 (Fig. 2) . These therapies thus aim to place parental nuclear DNA on a healthy mitochondrial background with no mtDNA from the mother present. However, technological limitations currently mean that carryover is possible, whereby some of the mother's mtDNA may be carried into the third-party cell with the transferred nuclear genetic material. These therapies can thus lead to the coexistence of several distinct sequences within cellular mtDNA populations. First, the non-pathogenic mtDNA from the third-party oocyte donor is present. Second, due to carryover, non-pathogenic mtDNA from the mother may be present. Third, due to carryover, pathogenic (mutant) mtDNA from the mother may be present (Fig. 2) . Figure 2. mtDNA segregation and gene therapies. A mother may possess two similar haplotypes, one wild type (blue) and one mutant (blue with red star). Therapies attempt to use a third-party with a potentially different mtDNA haplotype (yellow) to provide a healthy mtDNA background. Carryover in these therapies may result in an admixture of wildtype mother, mutant mother, and wildtype third-party mtDNA in a cell. If the two haplotypes (blue and yellow) proliferate differently, the offspring may evolve a predominance of third-party (lower left) or mother (lower right) mtDNA with time. In the latter case, if mutated mtDNA proliferates at a similar rate to its 'carrier' haplotype, the damaging mutation may be amplified to harmful levels in cells.
This admixture is stable if mother and oocyte donor mtDNA experience no proliferative differences (Fig. 2, centre) , and if the oocyte donor haplotype experiences a proliferative advantage then carried-over mtDNA will generally be reduced over time (Fig. 2 left) . However, a general proliferative advantage of the mother's haplotype can in principle lead to the amplification of the associated pathological mutation, working against the desired effect of the therapy to remove this mutation (Fig. 2 right) . This amplification can in principle occur even if the pathological mutation experiences a selective disadvantageif this disadvantage is of lower magnitude than the proliferative difference between haplotypes, the latter effect will still dominate.
It has been shown that in cellular admixtures in mice (and other species), such proliferative differences between haplotypes do indeed commonly exist ( Fig. 2 ; a selection of models and studies exhibiting this behaviour is given in . It has also been demonstrated that, while the direction and tissue-dependence of this differential proliferation are currently difficult to predict, its expected magnitude depends on the genetic difference between haplotypes (Burgstaller et al. , 2014) (Fig. 3 ). An important question to consider in gene therapies is thus, given the mtDNA diversity in human populations, what genetic differences are likely to arise in nuclear mother-oocyte donor pairings in therapeutic contexts, and are the proliferative differences in Fig. 2 
thus likely to arise?
If ∏ is the number of non-identical bases between two mtDNA genomes, i and j, then, intuitively, identical mtDNAs (∏ = 0) would be expected to behave identically, but the more different the mtDNAs (∏ > 0), the larger is the proliferative difference generally expected between the two. We define heteroplasmy, h, as the proportion of one 'foreign' mtDNA haplotype in a cellular admixture: hence, if a cell contains H 0 mtDNAs of its 'native' haplotype and H 1 mtDNAs of a 'foreign' haplotype, ℎ = 1 /( 0 + 1 ). Proliferative differences between haplotypes can be measured as a quantity a rate of proliferation of one mtDNA over another. In this picture, heteroplasmy h(t) is a function of an initial heteroplasmy h(t=0) and time t, with describing the rate of change of heteroplasmy:
. High values correspond to high proliferative differences (H 1 dominating over H 0 ), and hence high probabilities of amplification of one mtDNA type with time. For example, proliferative differences of average magnitude | | ≃ 0.008 per day have been measured between two mtDNA types of ∏ ≃ 100 in the livers of mice; this value of corresponds to an amplification of h from 0.05 (5% of one haplotype) to 0.49 (49% of that same haplotype) over one year (Burgstaller et al., 2014) .
A subset of recent evidence for proliferative differences between mtDNA haplotypes in mice is shown in Fig. 3 . Fig. 3A shows inferred values of | |, and the magnitude of proliferative differences between mtDNAs, in a variety of tissues for three mtDNA pairs (where ∏ = 18, 86, and 107). Fig. 3B shows the predictions that this behaviour of makes about absolute changes in heteroplasmy, for two putative admixtures beginning with 5% and 20% of a 'foreign' haplotype. For example, a haplotype differing from the 'native' type by ∏ ≃ 100 may readily experience amplification from 5% to 50% over one year.
For simplicity, these plots are limited to the behaviour over one year, but the trends are observed to continue throughout organismal lifetimes. For example, one observation in (Burgstaller et al., 2014) showed heteroplasmy in liver tissue rising from 5.9% to 81.8% over 680 days for a particular mtDNA pairing where ∏ = 108. There is thus evidence that, in mice, nucleotide differences around ∏ ∼ 100 are associated with proliferative differences capable of amplifying an admixed haplotype from a 5% minority to a pronounced cellular majority over the course of an organismal lifetime. But what are standard values of ∏ in actual human populations? And is this magnitude of genetic diversity expected to give rise to clinically relevant mtDNA behaviour, given that a mutant mtDNA load of 40-60% is often sufficient to cause morbidity, and it still poorly known what 'safe' levels may be in most cases (Wallace and Chalkia, 2013)?
Existing studies have characterised the nucleotide differences in contemporary human populations, finding typical differences of dozens of nucleotides across modern Europeans (Fu et al. , 2012) , greater diversity in Africa than in Europe (Briggs et al. , 2009) , and results confirming and expanding these observations across a broader geographical range (Lippold et al. , 2014) . A modern workflow has been developed to address related evolutionary questions (Blanco et al. , 2011) . However, to our knowledge, the interpretation of these statistics in terms of mtDNA segregation possibility and implications for disease is currently absent, as is an attempt to characterise the expected diversity in modern populations combining social (census) and biological (sequence) data.
Figure 3. mtDNA segregation and genetic differences in mice. A)
Magnitudes of segregation (proliferative differences between mtDNA types) in different tissues (points) in four different mtDNA pairings from (Burgstaller et al., 2014) . More pronounced segregation is observed in those pairings with the greatest genetic distance. Red line shows the mean trend of segregation with number of nucleotide differences; blue line shows the approximate maximum segregation strength across all tissues for mtDNA pairings with < 100 nucleotide differences. B) Ranges of expected heteroplasmy in mice after 1 year, given different initial heteroplasmies (h 0 ) and the mean (lower) and maximal (higher) segregation magnitude observed in mice. For example, the darker red curve shows that for an mtDNA pairing with 75 nucleotide differences, a maximal increase from ℎ = 0.05 to ℎ ≃ 0.3 is expected.
Materials and Methods

Materials -None.
Methods -We took a data-driven approach, harnessing the large numbers of human mtDNA sequence data now available through the NCBI database, as well as haplogroup data in the literature. mtDNA molecules may be categorised, via the presence or absence of diagnostic SNPs, into haplogroups, which are typically designated by an alphanumeric code and follow a moderately complex hierarchy. For example, at the coarsest level, all human mtDNAs so far recorded fall into haplogroup L. Subsets of L include N (which in turn includes R, containing H and V, etc.) and W, X, Y and others. A simplified tree of haplogroups is shown in Fig. 1A and illustrative geographical distributions are shown in Fig. 1B .
Data on the haplogroup makeup of 'precolonial populations', i.e. before early modern population mixing, from different geographical regions is available via MitoMAP (Lott et al. , 2013) . These data can be used to estimate the probability that an individual with maternal ancestry from a given region belongs to a given haplogroup.
Many specific mtDNA sequences corresponding to individual humans belonging to a given haplogroup are available via NCBI. Using these data, we sought to identify the expected genetic differences between pairs of individual, real human mtDNAs. To estimate these expected differences, we first characterised the expected differences between specific mtDNA samples within and between different haplogroups. For the purposes of this study we employ the convention that an individual is marked as a member of haplogroup category ℋ if it is (a) a member of ℋ and (b) not a member of any haplogroup that is a subgroup of ℋ. For example, is labelled as L if is in haplogroup L but not in any of the A, B, C, D, E, ... that are subgroups of L.
We obtained the > 30 mtDNA sequences available from NCBI Nucleotide database (NCBI, 2015) . Of these sequences ∼ 7.6 had straightforwardly interpretable haplogroup information, where the initial letter of the /haplogroup field was taken to be the haplogroup label. We categorised these records by this initial letter, then employed the following sampling protocol. Given a pair of haplogroups {ℋ 1 , ℋ 2 }, we picked at random a sequence belonging to ℋ 1 and picked at random a sequence belonging to ℋ 2 (ensuring that the two sequences were not the same sample if ℋ 1 = ℋ 2 ,). We used BLAST to record the number of sequence differences between these specific sampled sequences. For the purposes of this report we recorded the number of non-identical bases as the nucleotide difference ∏ ; we also note that indels commonly exist between sampled mtDNA sequences, further contributing to mtDNA diversity. We then built up a distribution of sequence differences over many (n=1000) sampled pairs of specific human mtDNAs from the given pair of haplogroups.
To connect more explicitly with medical policy, we next changed the scale of our analysis from haplogroups per se to the estimated haplogroup profiles of real human populations. First, we employed heuristic data from the MitoMAP project (Lott et al., 2013) estimating the haplogroup makeup of pre-colonial populations from different regions of the world, while noting that the actual census populations will usually have a very different makeup, especially in New World countries that experienced extensive overseas colonization. For each region, we randomly chose two haplogroups, each with a probability corresponding to that haplogroup's representation in the region of interest. We then randomly chose two specific mtDNA sequences from those two haplogroups. As above, we then used BLAST to determine the genetic difference between those specific sequences. We repeated this process many times to build up an expected distribution of the genetic differences between two randomly chosen members of the human population from that region.
As the UK is on the cusp of implementing gene therapies based on nuclear transfer, we then performed a more rigorous, population-based analysis for Britain. In order to estimate the probable levels of nucleotide diversity (∏ ) in mtDNA between two randomly selected British women, and hence the likely magnitude of proliferative differences between their mtDNA, a haplogroup profile of Britain was assembled, based on over 4,600 individuals. The majority of the UK samples represent ethnic Britons. To account for the fact that the modern UK population consists of many ethnicities, approximations of mtDNA haplogroup distributions for the two largest cities in the UK (London and Birmingham) were also constructed. These distributions are estimates, based on data from the 2011 census, immigration data, and published mtDNA haplogroup data for areas from which there has been mass immigration into the UK (see SI for details).
For each ethnic census category, an estimate of probable haplogroup composition was created (see SI for details on calculations), and the frequency values scaled by the numerical census data to yield expected haplogroup frequencies in London and Birmingham. For simplicity, the single letter level of nomenclature is used, with the exception of superhaplogroup L, for which its subgroups L0-3 are included.
Results
Fig. 4A
shows the resulting statistics on differences between sampled mtDNA sequences between haplogroup pairs. Several intuitive features are immediately observable. First, haplogroup L displays noticeably more intra-haplogroup differences than any other haplogroup. L haplogroups constitute the majority of African haplogroups (and have very deep branching times relative to non-African haplogroups) and are thus expected to include the most genetic diversity (Behar et al. , 2008) . Second, with the exception of L, diagonal elements (i.e. samples from a haplogroup compared to samples from the same haplogroup) show less diversity than off-diagonal elements (i.e. samples from a haplogroup compared to samples from a different haplogroup). Third, haplogroup pairings which are expected to be similar (for example, sister clades H and V) show decreased genetic diversity. The inset shows a breakdown of the L haplogroup into its immediate subgroups. The maximum (outer halo) and minimum (inner halo) nucleotide differences expected between a pair of randomly sampled mtDNA sequences (horizontal and vertical axes). The diagonal corresponds to pairs within the same haplogroup; off-diagonal elements correspond to pairs of mtDNAs from different haplogroups. Dataset size for each haplogroup is given in brackets; n=1000 samples were used for each pairing. Max h change shows, for a given magnitude of genetic diversity, the maximum expected change in heteroplasmy over one year starting at 5%, based on mouse models (Fig 3) . As described in the text, haplotype labels denote sequences that fall within a given category and not within any named subcategories of that category. Inset shows subgroups of the most-diverse L haplogroup. B) MtDNA differences between geographical regions. In blue, genetic differences between a pair of individuals randomly sampled from sets modelling populations within a given region of the world, using the MitoMAP (Lott et al., 2013) estimation of the (pre-colonial) haplogroup profile of different geographical regions. In black, expected differences in the general the modern non-urban UK population, and populations of London and Birmingham. Candlesticks show minimum, mean ± s.d., and maximum nucleotide differences between simulated pairs sampled from geographical regions. Explicit sample distributions are given in in lighter colours; max h change gives maximum expected change in heteroplasmy as in (A). SE Asia (in grey) has poorly characterised MitoMAP estimates.
A notable result from this analysis is that between haplogroups, differences of ∼50 SNPs are common, and, even within haplogroups, differences of ∼20 SNPs are common. This level of diversity may not seem substantial when compared to the ∼16 kilobases of total human mtDNA, but we draw attention to our previous observations that differences of ∼ 20 SNPs were enough to induce significant proliferative differences between haplotypes in mice, who also have a ∼16kb mtDNA genome (Burgstaller et al., 2014) . As shown in parentheses in Fig. 4A , the magnitudes of ∏ that likely emerge from pairwise haplotype samples match those responsible for dramatic mtDNA heteroplasmy changes in mouse models. Fig. 4A also provides a means of identifying a 'partner' for a given haplogroup that minimizes ∏ and hence the likelihood of damaging segregation. For example, given a mother with haplogroup B and a choice between donors from C, V, and L, Fig.4A shows that the B-V pairing minimizes maximum ∏, and thus affords the lowest risk of high segregation (see Discussion). Table 1 gives the estimated haplogroup makeup of the UK and two major cities, based on a combination of census and immigration data and a survey of worldwide mtDNA sequences (see Methods and SI). We underline that these quantities are principled estimates, but the summary statistics that arise from these estimates are robust to variation in the exact population frequencies, and is consistent with the behaviour expected from an ethnically mixed population based on more direct estimates (see below). 4B illustrates the distribution of nucleotide differences between individuals sampled from geographical regions, and rural vs. urban UK based on estimates in Table 1 , in this manner. It is immediately noticeable that pairs of individuals from Africa generally exhibit more diversity than pairs chosen from other regions, but it is striking that the expected genetic difference in many geographic regions is around ∏ ∼ 40-50 SNPs, often with a range between 10-100 SNPs. The substantial diversity expected in the UK and its cities is of a consistent magnitude with that expected from its population history, involving admixtures of African and Asian immigrants in addition to its original European state. Again, parenthesized numbers in Fig. 4B illustrate that these magnitudes of ∏ are readily able to induce pronounced heteroplasmy shifts in mice. Taken together, these results demonstrate that expected levels of mtDNA diversity in modern human populations are of comparable magnitude to those responsible for substantial segregation bias in a existing mammalian models, and so therapies that randomly pair women from these populations may be subject to potentially detrimental heteroplasmy changes over time.
Discussion
Our analysis clearly shows that, even within a geographical region restricted to the point of being dominated by a single mtDNA haplogroup, a ∏ = 10 − 100 is expected between randomly sampled individuals from that region. On a continental scale, expected differences are highest in Africa, as predicted from our knowledge of human population history, and comparably lower elsewhere. Comparably high, however, are the differences in the largest urban populations of the UK, where oocyte donor therapies will be implemented.
In mice, proliferative differences between haplogroups with ∏ ∼ 100 were sufficient in some tissues to cause amplification of one mtDNA type from 0.05 to 0.64 (i.e. a small representation to a notable majority) over an organismal lifetime (Fig. 2B ). There remains a wide range of questions involving the mapping from the murine model to the human system. One criticism of our argument may be that mtDNA segregation in humans may progress more slowly than in mice, reducing the magnitude of the effects we consider. However, segregation in humans has been observed to occur more rapidly than in mice (Wallace and Chalkia, 2013). Furthermore, evidence exists for pronounced segregation of a pathological mutation over very short times during embryo-fetal development (Monnot et al. , 2011) , suggesting the presence of mechanisms in humans that support fast segregation, and which could in principle also act on non-pathological mutations. Even in a conservative picture where mtDNA turnover rates are scaled by organismal lifetimes, amplification over the (longer) human lifetime will still be anticipated by analogy with the murine system. An important clinical example of the potentially high mtDNA segregation in human disease (again involving a pathological mutation) is described in Ref. (Mitalipov et al. , 2014) , in which an embryo selected for its low (12%) load of the 3243 mutation (Treff et al. , 2012) developed into an infant with >40% loads in blood and urine at six weeks of age, presenting with a range of (possibly unrelated) metabolic pathologies.
It is worth noting that, in addition to the unpredictability of segregation direction, the rate at which mtDNA segregation occurs is not simple and constantrather, it can depend on tissue type, organismal age and developmental stage (Burgstaller et al., 2014) , and complicating processes including the mtDNA bottleneck . It is thus not unreasonable to think that the 'averaged' rates reported here may be underestimates for a particular time period. We therefore highlight that, even from a conservative calculation of segregation rates, the likely genetic differences between humans randomly sampled from a population may well allow substantial amplification of a disease-carrying mtDNA haplotype over the timescale of a human lifetime.
We must also consider whether randomly sampling NCBI sequences is a good model for the mtDNA pairings likely to be involved in gene therapies. The counterexample of this would be a population consisting of many individuals with identical mtDNA sequences and a small number of individuals with different sequences. The NCBI, which assigns records to unique sequences, will likely have one record for the common sequence and one each for the rare different sequences. In this case, uniformly sampling the NCBI would underestimate the population fraction with the common sequence, and thus tend to overestimate mtDNA diversity. However, the ubiquity of many-SNP differences between records (see Fig.4 ) suggests that this problematic population structure is unlikely, and indeed, several contemporary studies have observed differences between each individual sample (Fu et al., 2012 , Lippold et al., 2014 . Additionally, socio-economic factors will give rise to structure in the pairings in clinical applications (which may either decrease or increase the expected ∏ ). Despite these complications, we consider our approximations appropriate for considering first-order bounds of likely behaviour in these populations exhibiting realistic human diversity.
The danger of pathological mutations 'hitchhiking' on favoured haplotypes and being amplified along with the haplotype is described in the introduction and has been discussed previously (Burgstaller et al., 2014 . An additional danger is the amplification of an initially rare mtDNA haplotype to the point where it competes with the dominant mtDNA type in a cell and causes pathologies through mismatched protein subunits or other mechanisms . The cooccurrence in a cell of two different, but both separately non-pathogenic, mtDNAs has been observed to result in adverse physiological changes (Sharpley et al. , 2012) . Segregation between mtDNA haplotypes, allowing an initially rare haplotype to proliferate and become amplified within a cell, has the potential to manifest and exacerbate both of these potential issues.
Figure 5. MtDNA differences expected with different haplotype matching strategies for a mother with haplogroup H1a. Distributions of nucleotide differences (min, mean +-sd, max) expected when pairing mtDNA from haplogroup H1a with randomly sampled mtDNA from our estimated London population, with randomly sampled mtDNA from haplogroup H, and with randomly sampled mtDNA from haplogroup H1a.
To diminish the likelihood of potentially harmful mtDNA segregation, which we argue is likely given the mtDNA diversity in the modern UK population, we urge experts involved in the implementation of these therapies to consider 'haplotype matching', i.e. choosing an oocyte donor with mtDNA as similar as possible to the mother's in clinical approaches. Methods to match haplotypes (minimise ∏ ) could include choosing maternal relatives of the mother with low or zero proportions of the pathological mutation under consideration, or choosing donors from a haplogroup as similar as possible to the mother's. To illustrate this latter strategy, Fig. 5 shows the range of expected ∏ values that could arise when a third-party donor is paired with a mother from haplogroup H1a. If no haplotype matching is employed, and the thirdparty donor is randomly sampled from our estimated London population, a maximum ∏ around 100 is possible (due to the pronounced population diversity illustrated in Fig. 4B ). Choosing a donor from haplogroup H decreases this maximum value to around 36 (that is, the maximal within-H diversity, shown on the diagonal of Fig. 4A ). More detailed matching, specifically choosing another H1a woman as the third-party, further limits the maximum ∏ to approximately 17. These lower values achieved through haplotype matching dramatically decrease the expected potential heteroplasmy changes (for example, in mice (Fig 2) , from a maximum of 5% → 49% over one year for ∏ = 100 to 5% → 8% over one year for ∏ = 17), thus immediately limiting the potential for detrimental segregation. Our results, and future findings from more detailed studies, can help provide a strategy for this matching processgiven a mother of known mtDNA haplogroup, choose from available oocyte donors so as to minimise the maximum genetic distance given in Fig. 4 . Such haplotype matching, which is in principle technically straightforward and economically marginal, Wallace DC, Chalkia D (2013) Mitochondrial DNA genetics and the heteroplasmy conundrum in evolution and disease. Cold Spring Harbor perspectives in biology 5, a021220.
Supplementary Information
I. UK city mtDNA haplogroup compositions
In order to produce a realistic approximation of the mitochondrial haplogroup composition of the two largest UK cities, London and Birmingham, an approach based on ethnic categories in the 2011 UK census and mt haplogroup data from corresponding regions and/or countries was employed. Ethnic composition data were downloaded from http://webarchive.nationalarchives.gov.uk, in which 18 categories were defined (see Table 1 for these category definitions and their frequencies in London and Birmingham). Then, for each ethnic category suitable mtDNA datasets were collated (see Table 2 for resultant haplogroup profiles).
